222 related articles for article (PubMed ID: 24103588)
1. Molecular bases of chronic lymphocytic leukemia in light of new treatments.
Rossi D; Ciardullo C; Spina V; Gaidano G
Immunol Lett; 2013; 155(1-2):51-5. PubMed ID: 24103588
[TBL] [Abstract][Full Text] [Related]
2. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
Danilov AV
Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
[TBL] [Abstract][Full Text] [Related]
4. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
5. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
6. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
Sharma S; Galanina N; Guo A; Lee J; Kadri S; Van Slambrouck C; Long B; Wang W; Ming M; Furtado LV; Segal JP; Stock W; Venkataraman G; Tang WJ; Lu P; Wang YL
Oncotarget; 2016 Oct; 7(42):68833-68841. PubMed ID: 27626698
[TBL] [Abstract][Full Text] [Related]
7. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
[TBL] [Abstract][Full Text] [Related]
8. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
9. Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.
Del Papa B; Baldoni S; Dorillo E; De Falco F; Rompietti C; Cecchini D; Cantelmi MG; Sorcini D; Nogarotto M; Adamo FM; Mezzasoma F; Silva Barcelos EC; Albi E; Iacucci Ostini R; Di Tommaso A; Marra A; Montanaro G; Martelli MP; Falzetti F; Di Ianni M; Rosati E; Sportoletti P
Clin Cancer Res; 2019 Dec; 25(24):7540-7553. PubMed ID: 31578228
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib: a paradigm shift in management of CLL.
Badar T; Burger JA; Wierda WG; O'Brien S
Expert Rev Hematol; 2014 Dec; 7(6):705-17. PubMed ID: 25387837
[TBL] [Abstract][Full Text] [Related]
11. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
Landau DA; Sun C; Rosebrock D; Herman SEM; Fein J; Sivina M; Underbayev C; Liu D; Hoellenriegel J; Ravichandran S; Farooqui MZH; Zhang W; Cibulskis C; Zviran A; Neuberg DS; Livitz D; Bozic I; Leshchiner I; Getz G; Burger JA; Wiestner A; Wu CJ
Nat Commun; 2017 Dec; 8(1):2185. PubMed ID: 29259203
[TBL] [Abstract][Full Text] [Related]
12. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
Reiff SD; Mantel R; Smith LL; Greene JT; Muhowski EM; Fabian CA; Goettl VM; Tran M; Harrington BK; Rogers KA; Awan FT; Maddocks K; Andritsos L; Lehman AM; Sampath D; Lapalombella R; Eathiraj S; Abbadessa G; Schwartz B; Johnson AJ; Byrd JC; Woyach JA
Cancer Discov; 2018 Oct; 8(10):1300-1315. PubMed ID: 30093506
[TBL] [Abstract][Full Text] [Related]
13. A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion.
Yin S; Gambe RG; Sun J; Martinez AZ; Cartun ZJ; Regis FFD; Wan Y; Fan J; Brooks AN; Herman SEM; Ten Hacken E; Taylor-Weiner A; Rassenti LZ; Ghia EM; Kipps TJ; Obeng EA; Cibulskis CL; Neuberg D; Campagna DR; Fleming MD; Ebert BL; Wiestner A; Leshchiner I; DeCaprio JA; Getz G; Reed R; Carrasco RD; Wu CJ; Wang L
Cancer Cell; 2019 Feb; 35(2):283-296.e5. PubMed ID: 30712845
[TBL] [Abstract][Full Text] [Related]
14. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Gozzetti A; Candi V; Brambilla CZ; Papini G; Fabbri A; Bocchia M
Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038
[TBL] [Abstract][Full Text] [Related]
15. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Ponader S; Chen SS; Buggy JJ; Balakrishnan K; Gandhi V; Wierda WG; Keating MJ; O'Brien S; Chiorazzi N; Burger JA
Blood; 2012 Feb; 119(5):1182-9. PubMed ID: 22180443
[TBL] [Abstract][Full Text] [Related]
16. Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
Gángó A; Alpár D; Galik B; Marosvári D; Kiss R; Fésüs V; Aczél D; Eyüpoglu E; Nagy N; Nagy Á; Krizsán S; Reiniger L; Farkas P; Kozma A; Ádám E; Tasnády S; Réti M; Matolcsy A; Gyenesei A; Mátrai Z; Bödör C
Int J Cancer; 2020 Jan; 146(1):85-93. PubMed ID: 31180577
[TBL] [Abstract][Full Text] [Related]
17. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.
Foluso O; Glick A; Stender M; Jaiyesimi I
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):63-9. PubMed ID: 26775273
[TBL] [Abstract][Full Text] [Related]
19. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
20. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
